Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Allergan : to cut over 1,000 jobs as it works to cut costs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/03/2018 | 08:02pm CEST
The Allergan logo is seen in this photo illustration

NEW YORK (Reuters) - Botox-maker Allergan Plc on Wednesday said it plans to cut over 1,000 jobs, more than 5 percent of its workforce, and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.

The company said the jobs and positions it plans to eliminate mostly focus on products and categories where the company has or expects to soon lose exclusivity.

The drugmaker said it expects to take a $125 million charge from the job cuts, primarily due to severance, most of which will be recorded in the fourth quarter of 2017.

Analysts estimated that the company had around $5.8 billion of net income in 2017 on roughly $15.9 billion of revenue, according to Thomson Reuters I/B/E/S.

It said cost savings from this restructuring program

should be around $300 million to $400 million per year. Allergan currently employs 18,000 people, according to its website. RBC Capital Markets analyst Randall Stanicky said the savings should add around 75 cents to $1 of earnings per share support going forward.

In November, the company said it was working on a program to expand its base business and reduce costs so it could return to earnings growth by 2019, but did not disclose a specific strategy at that point.

Allergan worked hard in recent years to protect Restasis, which generated about $1.5 billion in sales in 2016, from generic rivals. It struck a controversial deal with a Native American tribe in September to shield review of the patents by U.S. regulators, drawing the ire of lawmakers and rival drug companies.

But in October, a Texas federal judge invalidated Restasis patents on grounds that they cover ideas that are obvious, making it possible for rival generics to hit the market as early as next year. Allergan has appealed the ruling.

Shares of Allergan rose $1.02, or 0.6 percent, to $171.34 in afternoon trading on Wednesday.

(Reporting by Michael Erman; Editing by Chizu Nomiyama, Alistair Bell and David Gregorio)

By Michael Erman

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
10/17ALLERGAN : Announces Completion of Two Positive Safety Studies for Ubrogepant - ..
10/16ALLERGAN : FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasi..
10/11ALLERGAN : To Present Data From 13 Abstracts At The 2018 American Society For De..
10/10ALLERGAN : Launches Personalized Study Approach for Clinical Research Programs i..
10/05ALLERGAN : Launches New JUVEDERM IT Campaign Designed To Reach the Next Generati..
10/05ALLERGAN : Launches Personalized Study Approach for Clinical Research Programs i..
10/04ALLERGAN : Receives FDA Clearance To Treat Area Below The Jawline With CoolSculp..
10/03ALLERGAN : to Report Third Quarter 2018 Earnings and Host Conference Call and We..
10/03ALLERGAN : and the Allergan Foundation Support Breast Cancer Patients with New C..
10/03ALLERGAN : Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generat..
More news
News from SeekingAlpha
10/17Allergan to file U.S. marketing application for migraine med ubrogepant by ne.. 
10/16FDA OKs five-year claim for Allergan's Liletta IUD 
10/15Aclaris acquires rosacea cream from Allergan for $65M 
10/15FDA issues new guidance aimed at more efficient drug development 
10/15Healthcare 16-24% Target Net Gains Pace WallStars For October 
Financials ($)
Sales 2018 15 586 M
EBIT 2018 7 444 M
Net income 2018 -1 186 M
Debt 2018 23 058 M
Yield 2018 1,43%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,64x
EV / Sales 2019 5,46x
Capitalization 64 834 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 214 $
Spread / Average Target 12%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC12.04%64 834
JOHNSON & JOHNSON-4.19%374 137
PFIZER20.87%261 274
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%205 499
MERCK AND COMPANY23.44%191 007